PURPOSE: [(18)F]Flumazenil, which has the advantage of a longer half-life than [(11)C]flumazenil, is well known for determining of the central benzodiazepine receptor concentrations. However, [(18)F]flumazenil has not been widely used because fluctuating and relatively low yields render automatic production insufficient for routine and multicenter clinical trials. Here, we describe the results of a 2.5-year production study of [(18)F]flumazenil using an iodonium tosylate precursor, which allowed us to overcome the limitations of low and fluctuating radiochemical yields. PROCEDURES: We developed a clinically applicable production system by modifying a commercial synthesizer for the reliable and reproducible production of [(18)F]flumazenil for routine clinical studies. [(18)F]Flumazenil was prepared at 150 °C for 5 min in the presence of 4-methylphenyl-mazenil iodonium tosylate (4 mg), a radical scavenger (TEMPO, 1 mg), and [(18)F]KF/kryptofix 2.2.2 complex in N,N-dimethylformamide (1 ml). In the purification step, the final mixture was pretreated using different cartridges before performing high-performance liquid chromatography (HPLC) separation. Finally, we measured the radiochemical yield and performed quality-control assays on 94 batches. RESULTS: After carrying out additional purification before HPLC separation using a C18 plus Sep-Pak cartridge, the radiochemical yield of [(18)F]flumazenil increased from 34.4 ± 9.7 % (without the pretreatment, n = 24) to 53.4 ± 9.0 % (n = 94), and the lifetime of the semi-preparative column was five times that of the column without the C18 plus Sep-Pak cartridge. The mean-specific activity of [(18)F]flumazenil was 572 ± 116 GBq/μmol at the end of synthesis, and the radiochemical purity was more than 99 %, as determined by analytical HPLC and radio-TLC. [(18)F]Flumazenil prepared using this method satisfied all quality-control test standards and was highly stable for up to 6 h after preparation. CONCLUSIONS: The results of the 2.5-year production study using an iodonium tosylate precursor indicate that [(18)F]flumazenil has commercial and routine clinical applicability.
PURPOSE:[(18)F]Flumazenil, which has the advantage of a longer half-life than [(11)C]flumazenil, is well known for determining of the central benzodiazepine receptor concentrations. However, [(18)F]flumazenil has not been widely used because fluctuating and relatively low yields render automatic production insufficient for routine and multicenter clinical trials. Here, we describe the results of a 2.5-year production study of [(18)F]flumazenil using an iodonium tosylate precursor, which allowed us to overcome the limitations of low and fluctuating radiochemical yields. PROCEDURES: We developed a clinically applicable production system by modifying a commercial synthesizer for the reliable and reproducible production of [(18)F]flumazenil for routine clinical studies. [(18)F]Flumazenil was prepared at 150 °C for 5 min in the presence of 4-methylphenyl-mazenil iodonium tosylate (4 mg), a radical scavenger (TEMPO, 1 mg), and [(18)F]KF/kryptofix 2.2.2 complex in N,N-dimethylformamide (1 ml). In the purification step, the final mixture was pretreated using different cartridges before performing high-performance liquid chromatography (HPLC) separation. Finally, we measured the radiochemical yield and performed quality-control assays on 94 batches. RESULTS: After carrying out additional purification before HPLC separation using a C18 plus Sep-Pak cartridge, the radiochemical yield of [(18)F]flumazenil increased from 34.4 ± 9.7 % (without the pretreatment, n = 24) to 53.4 ± 9.0 % (n = 94), and the lifetime of the semi-preparative column was five times that of the column without the C18 plus Sep-Pak cartridge. The mean-specific activity of [(18)F]flumazenil was 572 ± 116 GBq/μmol at the end of synthesis, and the radiochemical purity was more than 99 %, as determined by analytical HPLC and radio-TLC. [(18)F]Flumazenil prepared using this method satisfied all quality-control test standards and was highly stable for up to 6 h after preparation. CONCLUSIONS: The results of the 2.5-year production study using an iodonium tosylate precursor indicate that [(18)F]flumazenil has commercial and routine clinical applicability.
Authors: Byung Chul Lee; Ji Sun Kim; Bom Sahn Kim; Ji Yeon Son; Soo Kyung Hong; Hyun Soo Park; Byung Seok Moon; Jae Ho Jung; Jae Min Jeong; Sang Eun Kim Journal: Bioorg Med Chem Date: 2011-03-21 Impact factor: 3.641
Authors: P Ryvlin; S Bouvard; D Le Bars; G De Lamérie; M C Grégoire; P Kahane; J C Froment; F Mauguière Journal: Brain Date: 1998-11 Impact factor: 13.501
Authors: Ikuo Odano; Christer Halldin; Per Karlsson; Andrea Varrone; Anu J Airaksinen; Raisa N Krasikova; Lars Farde Journal: Neuroimage Date: 2008-12-24 Impact factor: 6.556
Authors: Mikael Palner; Corinne Beinat; Sam Banister; Francesca Zanderigo; Jun Hyung Park; Bin Shen; Trine Hjoernevik; Jae Ho Jung; Byung Chul Lee; Sang Eun Kim; Lawrence Fung; Frederick T Chin Journal: EJNMMI Res Date: 2016-11-08 Impact factor: 3.138
Authors: Thibault Gendron; Gianluca Destro; Natan J W Straathof; Jeroen B I Sap; Florian Guibbal; Charles Vriamont; Claire Caygill; John R Atack; Andrew J Watkins; Christopher Marshall; Rebekka Hueting; Corentin Warnier; Véronique Gouverneur; Matthew Tredwell Journal: EJNMMI Radiopharm Chem Date: 2022-03-20
Authors: Se Jong Oh; Namhun Lee; Kyung Rok Nam; Kyung Jun Kang; Sang Jin Han; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi Journal: Front Neurosci Date: 2022-08-05 Impact factor: 5.152